Shorting still weak after UK ban ends

Figures from London-based, a provider of information on the securities financing industry, show that the percentage of shares outstanding on loan for three major UK banks Royal Bank of Scotland, Lloyds Banking Group and HSBC rose only slightly between January 15 and January 28. Royal Bank of Scotland shares on loan went from 0.22% to 0.62% of total shares outstanding, Lloyds shares from 1.19% to 1.3% and HSBC from 1.53% to 2.47%.

Barclays proved a slight exception. Its shares outstanding on loan rose more sharply after the ban was lifted, from 3.14% on January 15 to 5.81% on January 23. Over this same period, its share price dropped 61% from 130.4p to 51.2p.

However, with Barclays' share price recovering dramatically on January 26 to 88.7p, traders who had sold the stock short could have got badly burnt. The turnaround came after an open letter from the bank's chairman, Marcus Agius, and chief executive, John Varley, reassured investors that the bank was adequately capitalised and would not require an injection of government money.

There was minimal evidence of short positions being closed the next day, however, with Barclays shares outstanding on loan only dropping 0.02 percentage points to 5.79%. As of January 28, this level had risen again to 6.19%, while the share price stood at 107p.

On September 18, the FSA imposed a ban on short selling on 34 UK financial stocks. The practice had come under fire for allegedly accelerating - or even precipitating - the fall in UK bank shares. Proponents of short selling defend say the practice adds liquidity to the market and irons out pricing inaccuracies.

The FSA will continue to require disclosure of net short positions in UK financials until June 30 if the position reaches 0.25% of the institution's issued share capital.

See also: FSA to extend short selling oversight
Shorts changed

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here